Orion OyjORINF +4.81%100 PEG Ratio is 1.24 as of Jun. 29, 2026, which is 73% below its 10-year median of 4.64. GuruFocus rates ORINF with a GF Score™ of 100/100 and a GF Value™ of $82.46. The stock has 3 warning signs investors should review. Among 346 Drug Manufacturers companies, Orion Oyj ranks better than 60.12% on this metric.
PE Ratio without NRI / 5-Year EBITDA Growth Rate*
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Orion Oyj's PE Ratio without NRI is 18.87. Orion Oyj's 5-Year EBITDA growth rate is 15.20%. Therefore, Orion Oyj's PEG Ratio for today is 1.24.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Orion Oyj's PEG Ratio or its related term are showing as below:
ORINF'
s PEG Ratio Range Over the Past 10 Years
Min: 1.05 Med: 4.64 Max: 623.25
Current: 1.23
During the past 13 years, Orion Oyj's highest PEG Ratio was 623.25. The lowest was 1.05. And the median was 4.64.
ORINF's PEG Ratio is ranked better than 60.12% of 346
companies
in the Drug Manufacturers industry
Industry Median: 1.67
vs ORINF: 1.23
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Orion Oyj (OTCPK:ORINF) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Orion Oyj PEG Ratio Related Terms
Orion Oyj PEG Ratio Historical Data
* Premium members only.
The historical data trend for Orion Oyj's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Orion Oyj's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Oyj PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Oyj's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Orion Oyj's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Orion Oyj (ORINF) has a PEG Ratio of 1.24 as of Jun. 29, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Orion Oyj and its competitors. This is 73% below median its historical median of 4.64. Over the past decade, Orion Oyj's PEG Ratio has ranged from 1.05 to 623.25. According to the industry distribution chart, Orion Oyj ranks #138 out of 346 companies in the Drug Manufacturers industry, placing it in the top 39.9%.
Is Orion Oyj's PEG Ratio too high?
Orion Oyj's current PEG Ratio of 1.24 is 73% below median its 10-year median of 4.64. Over the past 10 years, this metric has ranged from a low of 1.05 to a high of 623.25. The Drug Manufacturers industry median PEG Ratio is 1.67. Orion Oyj's value of 1.24 is 25.7% below this industry median. Based on the distribution chart, Orion Oyj ranks #138 out of 346 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Orion Oyj has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does Orion Oyj's PEG Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Orion Oyj ranks #138 out of 346 companies for PEG Ratio. This puts Orion Oyj in the upper half of its industry. The industry median PEG Ratio is 1.67. Orion Oyj's value of 1.24 is 25.7% below this benchmark. Historically, Orion Oyj's own PEG Ratio has ranged from 1.05 to 623.25 over the past decade. While the company's 10-year median is 4.64 vs. the industry median of 1.67, Orion Oyj has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.67, based on 346 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Oyj's current PEG Ratio of 1.24 is 25.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Orion Oyj and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Oyj's current PEG Ratio is 1.24, which is 73% below median its own 10-year median of 4.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Oyj stock overvalued right now?
Orion Oyj (ORINF) has a current PEG Ratio of 1.24. The stock's GF Value™ is $82.46, compared to a current price of $82.75 — trading 0.4% above its estimated fair value. The current PEG Ratio is 1.24, which is 73% below median its 10-year median of 4.64 and 25.7% below the Drug Manufacturers industry median of 1.67. Orion Oyj's overall GF Score™ is 100/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Orion Oyj (ORINF), the current PEG Ratio is 1.24 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Oyj (ORINF) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Oyj stock appears to be overvalued.
The current stock price of $82.75 is trading 0.4% above its estimated GF Value™ of $82.46.
Key valuation signals for ORINF:
PEG Ratio: 1.24 (73% below median its 10-year median of 4.64)
GF Value™: $82.46 vs. price of $82.75 (0.4% above fair value)
Industry Position: 25.7% below the Drug Manufacturers median (#138 of 346)
No single metric tells the full story. See the ORINF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company predominantly focuses on treatments for central nervous system disorders, oncology, and respiratory diseases. Orion's customers include specialists and general practitioners, veterinarians, pharmacies, hospitals, and laboratories. The company mainly serves Finland but also has a presence in other European countries, North America and other countries.
100GF Score
Get the complete analysis for ORINF
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORINF has been successfully added to your 
